Psilocybin and Egocentricity in AUD: Pilot RCT Insights (NCT06235411)

Psilocybin Reduces Egocentric Bias in Alcohol Use Disorder: Key Findings

A pilot randomized controlled trial (RCT) published on September 29, 2026, reports that a single 25 mg dose of psilocybin significantly reduced egocentric bias in recently detoxified patients with alcohol use disorder (AUD) compared to a 1 mg active placebo. The trial, registered as NCT06235411, enrolled individuals with persistent depressive symptoms post-detoxification and assessed changes in social cognition using a visual perspective-taking task before and after administration.

Results showed that the high-dose psilocybin group exhibited a marked reduction in egocentric interference and egocentric superiority on reaction times, with no significant effect on altercentric bias or task accuracy. Subjective intensity of the psychedelic experience correlated with reduced egocentric superiority, suggesting a dose-response relationship.

Mechanistic Implications: Targeting Social Cognition in AUD

Psilocybin’s effect on egocentric bias may represent a novel mechanism for improving social cognition in AUD, a domain often overlooked in traditional treatment approaches. Egocentric bias—difficulty adopting another’s perspective—has been implicated in the social and interpersonal challenges faced by individuals with AUD. By selectively decreasing egocentricity without enhancing altercentric (other-focused) bias, psilocybin may help recalibrate self-other processing, potentially supporting recovery and social reintegration.

This mechanistic insight advances the field by moving beyond symptom reduction to target underlying cognitive processes. Notably, the study’s use of a validated visual perspective-taking task provides a quantifiable measure of social cognitive change, which could serve as an intermediate endpoint in future trials. This approach offers a concrete example of how psychedelic research can operationalize complex psychological constructs, a methodological advance not widely adopted in earlier studies.

Policy and Research Implications: Informing Future Trials and Guidelines

The findings from NCT06235411 may inform the design of larger, confirmatory trials and guide regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) in evaluating psychedelic-assisted therapies for substance use disorders. By identifying reduced egocentricity as a potential mechanism, researchers can refine outcome measures and tailor interventions to target social cognition, an area of high unmet need in AUD treatment.

For policymakers, these results underscore the importance of supporting mechanistic research alongside efficacy trials. Agencies funding mental health innovation, such as the National Institute on Alcohol Abuse and Alcoholism (NIAAA), may consider prioritizing studies that integrate cognitive and social endpoints. Clinicians and trial designers should note the importance of measuring both subjective and behavioral outcomes to capture the full spectrum of therapeutic effects.

Risks, Limitations, and Unknowns

While promising, the pilot nature of this RCT limits generalizability. The sample size was small, and participants were recently detoxified with persistent depressive symptoms, which may not reflect the broader AUD population. The study did not observe changes in altercentric bias or overall accuracy, suggesting that psilocybin’s effects may be specific rather than global enhancements of social cognition.

Safety data were not detailed in the abstract, and the intensity of the psychedelic experience was associated with cognitive changes, raising questions about optimal dosing and risk management. Adverse events, durability of effects, and potential for psychological distress remain key areas for further investigation.

Outlook: Next Steps for Psychedelic Research in AUD

Future research should replicate these findings in larger, more diverse samples and explore the durability of reduced egocentricity over time. Integrating mechanistic endpoints into phase 2 and phase 3 trials could accelerate understanding of how psychedelics affect social cognition and inform individualized treatment approaches. Regulatory and funding agencies may increasingly require such mechanistic evidence to support approval and reimbursement decisions.

For the field, this study illustrates the value of targeting cognitive and social processes in substance use disorder research, moving beyond symptom checklists to address the underlying drivers of recovery and relapse. As the evidence base grows, stakeholders must balance enthusiasm with rigorous evaluation of safety, efficacy, and real-world applicability.

Reviewed by Dr. Alex M. Carter, PhD (Neuroscience), Psychedelic Research Journal. How we research: All claims verified against primary trial registry and publication as of 2026-10-01.